Although clinical management of movement disorders tends to focus on pharmacological therapy, this landscape is gradually changing as more therapeutic evidence for nonpharmacological treatments of movement disorders has been gathered to support more clinical recommendations with various options, ranging from physiotherapy, occupational therapy, speech and language therapy, to cognitive and behavioral therapy, and, increasingly, assistive technology (AT) is used as part of these interventions. Recently, digital technologies have been integrated into different types of AT, especially mobile-based solutions, to be either part of interdisciplinary nonpharmacological interventions or as a solo device in the management of movement disorder conditions where most literature concentrates on Parkinson's disease (PD) and tremor disorders. Using PD as the prototypical example of movement disorder conditions in this chapter, the authors identified levels of advancement, trends, and challenges in the growing area of digital assistive technology (DAT), and highlighted its potential to bridge the treatment gap by providing clinical relevant examples in the four areas of motor aspects of experiences of daily living of the Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part II), including orofacial function, upper limb function, mobility, and sleep. Even though the advancements are not equal, they represent opportunities and challenges for the stakeholders who are involved in the care of PD to bring these technologies forward to patients as the final users, with the ultimate shared goal for patients to use DATs that help their symptoms. Once a patient's viewpoint and understanding are shared, synced, and agreed by individual stakeholders who are involved in the development of a particular DAT, we will be closer to having a DAT that enhance patient's quality of life and add to our patient's pleasure and enjoyment. It can be done! © 2024 Elsevier Inc. All rights reserved.
Engaging multi-stakeholders to develop a great digital assistive technology that Parkinson's disease patients love, value, and use to improve motor aspects of daily living
Tinazzi, Michele
2024-01-01
Abstract
Although clinical management of movement disorders tends to focus on pharmacological therapy, this landscape is gradually changing as more therapeutic evidence for nonpharmacological treatments of movement disorders has been gathered to support more clinical recommendations with various options, ranging from physiotherapy, occupational therapy, speech and language therapy, to cognitive and behavioral therapy, and, increasingly, assistive technology (AT) is used as part of these interventions. Recently, digital technologies have been integrated into different types of AT, especially mobile-based solutions, to be either part of interdisciplinary nonpharmacological interventions or as a solo device in the management of movement disorder conditions where most literature concentrates on Parkinson's disease (PD) and tremor disorders. Using PD as the prototypical example of movement disorder conditions in this chapter, the authors identified levels of advancement, trends, and challenges in the growing area of digital assistive technology (DAT), and highlighted its potential to bridge the treatment gap by providing clinical relevant examples in the four areas of motor aspects of experiences of daily living of the Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS Part II), including orofacial function, upper limb function, mobility, and sleep. Even though the advancements are not equal, they represent opportunities and challenges for the stakeholders who are involved in the care of PD to bring these technologies forward to patients as the final users, with the ultimate shared goal for patients to use DATs that help their symptoms. Once a patient's viewpoint and understanding are shared, synced, and agreed by individual stakeholders who are involved in the development of a particular DAT, we will be closer to having a DAT that enhance patient's quality of life and add to our patient's pleasure and enjoyment. It can be done! © 2024 Elsevier Inc. All rights reserved.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
